TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  Benzinga

Why Is Adaptive Biotechnologies Stock Trading Lower After Natera's Over $400 Million Deal?

Benzinga Logo Benzinga By Vandana Singh
Why Is Adaptive Biotechnologies Stock Trading Lower After Natera's Over $400 Million Deal?

Adaptive Biotechnologies' stock dropped after Natera acquired Foresight Diagnostics for $275 million upfront, raising competitive concerns in the blood-cancer minimal residual disease (MRD) market.

Insights
PLTR   neutral

Reported strong quarterly results despite market volatility


ADPT   negative

Stock dropped 12.63% due to potential competitive threat from Natera's acquisition and reduced M&A speculation after previous Abbott-Exact Sciences deal